svReg: Structural varying‐coefficient regression to differentiate how regional brain atrophy affects motor impairment for Huntington disease severity groups

@article{Kim2021svRegSV,
  title={svReg: Structural varying‐coefficient regression to differentiate how regional brain atrophy affects motor impairment for Huntington disease severity groups},
  author={Rakheon Kim and Samuel M{\"u}ller and Tanya P. Garcia},
  journal={Biometrical Journal},
  year={2021},
  volume={63},
  pages={1254 - 1271}
}
For Huntington disease, identification of brain regions related to motor impairment can be useful for developing interventions to alleviate the motor symptom, the major symptom of the disease. However, the effects from the brain regions to motor impairment may vary for different groups of patients. Hence, our interest is not only to identify the brain regions but also to understand how their effects on motor impairment differ by patient groups. This can be cast as a model selection problem for… 

References

SHOWING 1-10 OF 49 REFERENCES

Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.

These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD and assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.

Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington’s Disease Phenotype

The authors' cognitive control cluster scores show sensitivity to changes in basal ganglia both within and outside the striatum that may not be captured by examining only motor scores.

Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study

Nearly all motor domain scores showed greater abnormality with increasing proximity to diagnosis, although bradykinesia and chorea were most highly associated with diagnostic immediacy.

COX REGRESSION WITH EXCLUSION FREQUENCY-BASED WEIGHTS TO IDENTIFY NEUROIMAGING MARKERS RELEVANT TO HUNTINGTON'S DISEASE ONSET.

A novel variable selection technique is proposed that casts the problem into several smaller dimensional settings and extracts from this intermediary step the relative importance of each predictor through data-driven weights called exclusion frequencies, and results yield low false discovery rates and a high geometric mean of sensitivity and specificity.

Indexing disease progression at study entry with individuals at‐risk for Huntington disease

Results of a longitudinal receiver operating characteristic (ROC) analysis showed that CAPS had a relatively strong ability to predict individuals who became diagnosed, especially in the first 2 years.

Unified Huntington's disease rating scale: reliability and consistency

The limited longitudinal database indicates that the UHDRS may be useful for tracking changes in the clinical features of HD over time and there was an excellent degree of interrater reliability for the motor scores.

Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study

These findings represent the most thorough documentation of a clinical battery for experimental therapeutics in stages of premanifest HD, the time period for which effective intervention may provide the most positive possible outcome for patients and their families affected by this devastating disease.

Unified Huntington's disease rating scale: Reliability and consistency

  • K. KieburtzJ. Penney V. Hunt
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 1996
The limited longitudinal database indicates that the UHDRS may be useful for tracking changes in the clinical features of HD over time and there was an excellent degree of interrater reliability for the motor scores.

Diagnostic criteria for Huntington's disease based on natural history

It is suggested that expanded diagnostic criteria for HD should be adapted to better reflect the natural history of the disease, to enable the conduct of clinical trials in premanifest subjects targeting prevention of neurodegeneration, and to facilitate earlier symptomatic treatment.